A team of researchers at Kumamoto University has uncovered a groundbreaking mechanism in the formation of harmful protein aggregates that lead to neurodegenerative diseases such as Parkinson’s Disease.
Boehringer reinforces interest in NASH with new $2bn deal – Pharmaceutical Technology
Share this article Boehringer will use Ribo’s RIBO-GalSTAR platform to identify and develop therapies for NASH. Credit: Michael Vi via Shutterstock. Boehringer Ingelheim is intensifying